Eson Ekpo, M.D.

Stanford IM Alum, current Advanced Heart Failure Fellow, trained fine artist, former CCU/CVICU RN, Integrative & Preventative Cardiologist, future HF Specialist

[Eson Ekpo, M.D. @CardiBeatMD]

Part education, part advocacy, but mostly recruiting future vessels of change into the field of cardiology. #UICCOM #UMED #HealthcareDisparities

[Eson Ekpo, M.D. @CardiBeatMD]

Proud to share our new @American_Heart Scientific Statement in Circulation.
Up to 60% of hospitalized CV patients are affected. Early recognition + nutrition support matter. 🫀#Cardiology #HeartFailure #CardioTwitt https://t.co/jEGna0QgOI

[Eson Ekpo, M.D. @CardiBeatMD]

In Chicago and had to visit my mentors from medical school. Happy to see my artwork is still hanging up in the study lounge.#UICCOM #UIC

[Eson Ekpo, M.D. @CardiBeatMD]

The struggles of pulling off a manuscript in the middle of a busy AHF fellowship.

[Eson Ekpo, M.D. @CardiBeatMD]

Excited to be presenting at this year’s Urban Medicine Policy and Advocacy Forum. I am proud of the work my medical school does and the medical students who are committed to partnering with local organizations to address health disparities through service learning and advocacy.

[Eson Ekpo, M.D. @CardiBeatMD]

Had an integrative medicine question on my HF practice questions today😁

[Eson Ekpo, M.D. @CardiBeatMD]

When ADHD & dyslexia are not excuses for failure, so I create 18-month structured schedules to study for boards. I later learned that this is called an individualized learning plan and is often used for students who are neurodivergent. Where were ILRs when I was in school?

[Eson Ekpo, M.D. @CardiBeatMD]

Taking some time to put on my preventative cardiology hat…

Apolipoprotein B outperforms low density lipoprotein particle number as a marker of cardiovascular risk in the UK Biobank | European Journal of Preventive Cardiology | Oxford Academic https://t.co/wr1pdWTUWj

[Eson Ekpo, M.D. @CardiBeatMD]

Determined to understand this thing we call Transplant Cardiology; but why does every other paragraph say there’s not enough evidence to recommend…. If the experts don’t know, how am I supposed to know #AHFTC

[Eson Ekpo, M.D. @CardiBeatMD]

I was crazy enough to join a busy Integrative Medicine Fellowship in the middle of my cardiology training, but I am glad I did. It was worth it.! One more fellowship to go. #IntegrativeMedicine #IntegrativeCardiology #AIHM

[Jeff Teuteberg @JeffTeuteberg]

👀 @Stanford_HF surpassed 2⃣5⃣0⃣0⃣🫀transplants in program history this month‼️
Congratulations to the entire team that makes this possible 🙌🎆🥳
@Stanford @stanfordctsurg @StanfordMed @StanCVFellows @StanfordCVI @ISHLT @HFSA @tcccop @KiranKhush1 @EldrinL @Erik_Henricksen

[Eson Ekpo, M.D. @CardiBeatMD]

(10/10) HELIOS-B shows RNAi therapy can significantly improve survival and HF outcomes in ATTR-CM. Vutrisiran’s success establishes TTR gene silencing as a viable strategy alongside stabilizers, heralding a new era for #Amyloidosis care.
#CardioTwitter #JACC

[Eson Ekpo, M.D. @CardiBeatMD]

(1/10) 🧬Vutrisiran, a subcutaneous RNAi therapy, significantly reduces all-cause mortality & CV events in the HELIOS-B trial - benefits seen even with background tafamidis. #CardioTwitter #ATTR #HeartFailure #RNAi #JACC https://t.co/ptVOWymN5V

[Eson Ekpo, M.D. @CardiBeatMD]

(9/10) #Vutrisiran (SC q3mo) is poised to join tafamidis as a therapy for ATTR-CM. Its q3-month dosing is more convenient than patisiran (IV q3w). A silencer + stabilizer combination might offer added benefit, but needs confirmation in future trials. #Amyloidosis